Results 91 to 100 of about 31,195 (193)
Tigecycline: Its potential for treatment of brucellosis
The in vitro efficacy and synergistic activity of tigecycline in comparison with other antimicrobials used in brucellosis, were tested for 16 Brucella melitensis strains by the E-test method.
Arman, Dilek +7 more
core +2 more sources
The successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented.
Jiawei Zeng +7 more
doaj +1 more source
Immunomodulatory Effects of Tigecycline in Balb/C Mice
Tigecycline is a glycylcycline antibiotic approved by the FDA for the treatment of complicated infections. Despite its effectiveness, the FDA announced a warning of increasing mortality associated with its use. There is, however, no clear explanation for
Elhayek Shada Y. +4 more
doaj +1 more source
Yuansu Jiang,* Xiaojiong Jia,* Yun Xia Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China *These authors contributed equally to this work Background: Tigecycline ...
Jiang Y, Xia Y, Jia X
core
Susceptibility profiles of nine tigecycline-resistant and one tigecycline-susceptible strain.
Footnote. KB, Kirby-bauer; BMD, broth microdilution; MIC, minimum inhibitory concentration(test by BMD and E-test method) ; ATCC 25922 quality control strain KB value range from 20–27 cm, MIC range from 0.03–0.25 µg/mL.Susceptibility profiles of nine ...
Xin Hu (38924) +5 more
core +1 more source
Background Tigecycline is widely used to treat a variety of bacterial infections despite concerns regarding increased mortality in severe infections.
Sol Jin +13 more
doaj +1 more source
<i>Background:</i> Colistin sulfate and levofloxacin, alone and in combination with tigecycline, were investigated for their in vitro activities and postantibiotic effects (PAEs) on6 meropenem-resistant<i> Acinetobacter baumannii</i ...
Berna Özbek +3 more
core +1 more source
Mohamed M Ibrahim,1 Abdulla M Abuelmatty,2 Gehan H Mohamed,3 Mohsen A Nasr,4 Amal K Hussein,5 Mohy El Deen Ebaed,6 Hatem A Sarhan5 1Department of Clinical Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt; 2Department of Pharmacy, Jahra ...
Sarhan HA +6 more
core
The tigecycline resistance mechanisms in Gram-negative bacilli [PDF]
Tigecycline, hailed as a pivotal agent in combating multidrug-resistant bacterial infections, confronts obstacles posed by the emergence of resistance mechanisms in Gram-negative bacilli.
Henan Li, Zhiren Wang
core +1 more source
Hal Tucker, Michele Wible, Ashesh Gandhi, Alvaro QuintanaPfizer Inc, Collegeville, PA, USABackground: Acinetobacter infections, especially multidrug-resistant (MDR) Acinetobacter infections, are a global health problem.
Tucker H, Quintana A, Wible M, Gandhi A
core

